|
page 1/25
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Froissart A, Buffet M, Veyradier A, Poullin P, Provot F, Malot S, Schwarzinger M, Galicier L, Vanhille P, Vernant JP, Bordessoule D, Guidet B, Azoulay E, Mariotte E, Rondeau E, Mira JP, Wynckel A, Clabault K, Choukroun G, Presne C, Pourrat J, Hamidou M, Coppo P. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med. 2012;40:104-111. Thèmes : Hémostase ; Plasmaphérèse - Echange plasmatique ; maj-2012-11

|
|
|
George JN, Vesely SK. A seasonal association of incident cases of thrombotic thrombocytopenic purpura was not observed in the Oklahoma TTP-HUS Registry. Transfusion. 2012;52:1593-1594. Thèmes : Hémostase ; maj-2012-11

|
|
|
Holz JB. The TITAN trial--assessing the efficacy and safety of an anti-von Willebrand factor Nanobody in patients with acquired thrombotic thrombocytopenic purpura. Transfus Apher Sci. 2012;46:343-346. Thèmes : Hémostase ; maj-2012-11

|
|
|
|
|
|
|
|
|
Kumpel BM. Would it be possible to prevent HPA-1a alloimmunization to reduce the incidence of fetal and neonatal alloimmune thrombocytopenia? Transfusion. 2012;52:1393-1397. Thèmes : Hémostase ; maj-2012-11

|
|
|
|
|
Park SJ, Shin JI. Another beneficial effect of rituximab on refractory and relapsing thrombotic thrombocytopenic purpura: the role of interleukin-12 suppression? Crit Care Med. 2012;40:1391. Thèmes : Hémostase ; maj-2012-11

|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
page 1/25
|